Technical Analysis for KNTE - Kinnate Biopharma Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Up | Flat |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Bollinger Band Squeeze | Range Contraction | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
Doji - Bearish? | Reversal | 0.00% | |
Earnings Movers | Other | 0.00% | |
Bullish Engulfing | Bullish | -0.39% | |
Bollinger Band Squeeze | Range Contraction | -0.39% | |
Narrow Range Bar | Range Contraction | -0.39% | |
BB Squeeze Started | Range Contraction | -0.39% | |
Narrow Range Bar | Range Contraction | 0.79% | |
Earnings Movers | Other | 0.79% |
Alert | Time |
---|---|
10 DMA Resistance | about 15 hours ago |
Possible NR7 | about 16 hours ago |
60 Minute Opening Range Breakout | about 18 hours ago |
Rose Above Previous Day's High | about 18 hours ago |
Rose Above 10 DMA | about 18 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 03/18/2024
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors for treating genomically defined cancers. The company's lead product candidate is KIN002787, which is a rapidly accelerated fibrosarcoma inhibitor that is in preclinical stage for the treatment of patients with lung cancer, melanoma, and other solid tumors. Its other products in preclinical stage include KIN003, which are small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors (FGFR)2 and FGFR3 genes; and small molecule research programs, including a Cyclin-Dependent Kinase 12 inhibitor in its KIN004 program. Kinnate Biopharma Inc. was founded in 2018 and is headquartered in San Diego, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Solid Tumors Melanoma Lung Cancer Sarcoma Fibroblast Growth Factor Fibroblast Growth Factor Receptor Fibrosarcoma
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Solid Tumors Melanoma Lung Cancer Sarcoma Fibroblast Growth Factor Fibroblast Growth Factor Receptor Fibrosarcoma
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 7.185 |
52 Week Low | 1.04 |
Average Volume | 308,100 |
200-Day Moving Average | 2.33 |
50-Day Moving Average | 2.45 |
20-Day Moving Average | 2.53 |
10-Day Moving Average | 2.56 |
Average True Range | 0.07 |
RSI (14) | 56.14 |
ADX | 23.19 |
+DI | 22.60 |
-DI | 13.82 |
Chandelier Exit (Long, 3 ATRs) | 2.45 |
Chandelier Exit (Short, 3 ATRs) | 2.45 |
Upper Bollinger Bands | 2.63 |
Lower Bollinger Band | 2.43 |
Percent B (%b) | 0.61 |
BandWidth | 7.55 |
MACD Line | 0.04 |
MACD Signal Line | 0.04 |
MACD Histogram | -0.0045 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 2.60 | ||||
Resistance 3 (R3) | 2.60 | 2.58 | 2.59 | ||
Resistance 2 (R2) | 2.58 | 2.57 | 2.58 | 2.58 | |
Resistance 1 (R1) | 2.57 | 2.56 | 2.57 | 2.57 | 2.58 |
Pivot Point | 2.55 | 2.55 | 2.55 | 2.55 | 2.55 |
Support 1 (S1) | 2.54 | 2.54 | 2.54 | 2.54 | 2.52 |
Support 2 (S2) | 2.52 | 2.53 | 2.52 | 2.52 | |
Support 3 (S3) | 2.51 | 2.52 | 2.51 | ||
Support 4 (S4) | 2.51 |